- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Latest Conference Articles
New Options for Renal Cell Carcinoma Could Offer Hope, But Sequencing and a Personalized Approach Are Critical
February 12th 2021, 10:20pm
Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.
Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype
February 12th 2021, 8:45pm
The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype
February 12th 2021, 6:30pm
Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.
Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies
February 11th 2021, 9:56pm
Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.
Starting Treatment With Lenvima at a Higher Dose Improves Quality of Life and Symptom Control in Type of Kidney Cancer
February 11th 2021, 8:49pm
A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.
New Combination Could Prove Beneficial After Immunotherapy in Patients with Clear Cell RCC
February 11th 2021, 6:59pm
The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.
Early Use of Fixed-Duration Venclexta-Rituxan Combo in Patients with Relapsed/Refractory CLL Effective, And Does Not Compromise Subsequent Therapy Response in Patients Who Need Retreatment
December 14th 2020, 4:00pm
American Society of Hematology Annual Meeting
More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.
Patients Who Experienced Chemotherapy-Induced Nausea/Vomiting During First Cycle of Cancer Treatment May Be at Greater Risk for Recurrence of the Side Effect
December 12th 2020, 7:00pm
Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.
Tesetaxel with Reduced Dose of Xeloda Improves Progression-Free Survival in Breast Cancer
December 12th 2020, 4:00pm
Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.
Side Effects from Oral Paclitaxel Plus Encequidar May Be Mitigated with Anti-Nausea Medications, Loperamide
December 11th 2020, 9:30pm
An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.
Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years
December 6th 2020, 7:30pm
American Society of Hematology Annual Meeting
The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.
Interventions Improve Survival, Quality of Life for Patients Experiencing Financial Toxicity
December 6th 2020, 7:00pm
American Society of Hematology Annual Meeting
Dr. Knight presents findings that suggest financial intervention can improve mortality rate in patients with hematologic malignancy at the 2020 ASH Meeting.
Venclexta-Rituxan Combo Continues to Show Survival Benefit Through 5 Years in Relapsed/Refractory CLL
December 5th 2020, 9:33pm
American Society of Hematology Annual Meeting
Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.
Data Support Fixed-Treatment Duration of Imbruvica/Venclexta Combo Could Lead to Treatment Discontinuation in Certain Patients With CLL/SLL
December 5th 2020, 9:07pm
American Society of Hematology Annual Meeting
Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.
High-Dose Imetelstat Could Offer Patients with High-Risk Myelofibrosis Improved Overall Survival
December 5th 2020, 8:00pm
American Society of Hematology Annual Meeting
An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.
CURE®’s 8th Annual MPN Heroes Program Honors ‘Team of Warriors’ Who Have Overcome Challenges in Myeloproliferative Neoplasms
December 5th 2020, 3:00pm
Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.
Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma
December 4th 2020, 2:00pm
Educated Patient® Multiple Myeloma Summit
Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.
How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment
November 11th 2020, 7:00pm
Educated Patient® Leukemia and Lymphoma Summit
CAR-T cell therapy is a relatively new treatment option for patients with blood cancers, but it’s one showing promise across the landscape. Here’s what you need to know.
Extraordinary Healer® Award for Oncology Nursing 2020
October 20th 2020, 8:00pm
Extraordinary Healer® Award for Oncology Nursing
View the entire Extraordinary Healer® Award for Oncology Nursing virtual presentation here!
Susan G. Komen Greater New York City 4th Annual Patient Navigation Town Hall Livestream
June 22nd 2020, 9:08pm
Susan G. Komen Greater New York City Annual Patient Navigation Town Hall
In partnership with CURE®, Susan G. Komen Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Oncologists, community health workers and patient navigators will get together on June 23rd, via webinar, to discuss the impact of the COVID-19 pandemic on the cancer landscape and how professionals and patients can navigate the fallout moving forward.
Advice for the Newly Diagnosed: How to Play an Active Role in Your Treatment
March 28th 2020, 1:00am
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
“Often you think we’re the victim, but there’s a lot that you can do to be your own advocate and participate in your healing,” says stage four metastatic breast cancer thriver Nalie Agustin.
Genetic Testing May Offer More Through Clinical Trial Matching
March 24th 2020, 7:06pm
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
Genetic testing offers a care team a wealth of knowledge to help them craft treatments, but it also can help match patients to clinical trials for potentially better outcomes.
Financial Assistance Programs Offer Out-of-Pocket Cost Relief to Patients with Cancer
March 24th 2020, 12:15am
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
Patients faced with cancer are also faced with tough uphill financial battles, but there are assistance programs that can help.
'Knowledge is Power' in Genetic Testing for Hereditary Cancer
March 21st 2020, 12:00am
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
Having the right understanding and information of a patient’s genetics can not only help treat cancer but also help prevent it.
A Metastatic Breast Cancer Thriver Shares the Importance of Understanding Your Diagnosis
March 20th 2020, 12:00am
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
Understanding a diagnosis is not just something for a patient's care team, the patient needs to understand their diagnosis as well.
The Importance of Biomarker Testing for Patients and Their Families
March 19th 2020, 1:09am
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
Understanding biomarkers specific to breast cancer can guide treatment plans and help families with a history of the disease take preventive measures.
Here's What Patients With Breast Cancer Need to Know About CDK 4/6 Inhibitors
March 18th 2020, 10:00pm
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
As CDK 4/6 inhibitors become a bigger part of the treatment of breast cancer, CURE® sat down with clinical nurse specialist Patricia Jakel to discuss the essentials about the drug.
Advice to the Newly Diagnosed: Get a Second Opinion
March 14th 2020, 10:00pm
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
Don’t be worried to get a second opinion — it could save your life.
Utilizing the Patient Perspective as a Patient Advocate
March 13th 2020, 10:27pm
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
Being a patient with cancer gives you a unique perspective that can become beneficial when serving as an advocate for others.
What to Do After You Hear the Words 'You Have Cancer'
March 9th 2020, 10:02pm
Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit
If patients take a deep breath and concentrate on the journey ahead after receiving a diagnosis, they can find a path forward, says one metastatic breast cancer thriver.
Latest News
FDA Grants Orphan Drug Designation to Novel CAR-T Cell Therapy to Treat Waldenstrom Macroglobulinemia, a Rare Type of Cancer
New Resource ‘Empowers’ Patients With Breast Cancer That Has Spread to the Brain With Much Needed Information
Cancer Boosted My Empathy, But Anger Is Starting to Rear Its Head
FDA Approves Breyanzi for Previously Treated Large B-Cell Lymphoma